MSTN and Duchenne muscular dystrophy: Pharmacological manipulation of myostatin has already been tested as a therapeutic approach [25]: Myostatin inhibition may theoretically be beneficial in diseases with muscle weakness such as Duchenne muscular dystrophy or rheumatoid arthritis and was already tested [25].